Considerations for Opioid Use Disorder Treatment From Policy Makers’ Experiences With COVID-19 Policy Flexibilities
Psychiatric Services · 2024
DOI: 10.1176/appi.ps.20230260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychiatric Services, 2024. Verfasst von Lavonia Smith LeBeau und 7 weiteren Autor:innen. Beteiligte Einrichtung: Customer Value Partners, Washington, D.C. (Smith LeBeau); IBM Consulting, Bethesda (White); The Lewin Group, Optum Serve, Boston (Henke); Chobanian &…. Hauptthemen laut MEDLINE: Opioid-Related Disorders, COVID-19, Health Policy, Qualitative Research. Die Arbeit nennt 14 Literaturangaben.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
OBJECTIVE: This qualitative study aimed to examine how states implemented COVID-19 public health emergency-related federal policy flexibilities for opioid use disorder treatment from the perspective of state-level behavioral health policy makers. Recommendations are given for applying lessons learned to improve the long-term impact of these flexibilities on opioid use disorder treatment. METHODS: Eleven semistructured interviews were conducted with 13 stakeholders from six state governments, and transcripts were qualitatively coded. Data were analyzed by grouping findings according to state-, institution-, and provider-level barriers and facilitators and were then compared to identify overarching themes. RESULTS: Policy makers expressed positive opinions about the opioid use disorder treatment flexibilities and described benefits regarding treatment access, continuity of care, and quality of care. No interviewees reported evidence of increased adverse events associated with the relaxed medication protocols. Challenges to state-level implementation included gaps in the federal flexibilities, competing state policies, facility and provider liability concerns, and persistent systemic stigma. CONCLUSIONS: As the federal government considers permanent adoption of COVID-19-related flexibilities regarding opioid use disorder treatment policies, the lessons learned from this study are crucial to consider in order to avoid continuing challenges with policy implementation and to effectively remove opioid use disorder treatment barriers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Customer Value Partners, Washington, D.C. (Smith LeBeau); IBM Consulting, Bethesda (White); The Lewin Group, Optum Serve, Boston (Henke); Chobanian & Avedisian School of Medicine, Boston University, Boston (Hyde, Weisbe…
Zitieren
APA
LeBeau, L. S., White, M. C., Henke, R. M., Hyde, J., Sarpong, A., Weisberg, R. B., Livingston, N. A., & Mulvaney-Day, N. (2024). Considerations for Opioid Use Disorder Treatment From Policy Makers’ Experiences With COVID-19 Policy Flexibilities. Psychiatric Services. https://doi.org/10.1176/appi.ps.20230260
Vancouver
LeBeau LS, White MC, Henke RM, Hyde J, Sarpong A, Weisberg RB, et al. Considerations for Opioid Use Disorder Treatment From Policy Makers’ Experiences With COVID-19 Policy Flexibilities. Psychiatric Services. 2024. doi:10.1176/appi.ps.20230260
BibTeX
@article{LeBeau2024,
author = {LeBeau, Lavonia Smith and White, Mackenzie C and Henke, Rachel Mosher and Hyde, Justeen and Sarpong, Alexis and Weisberg, Risa B and Livingston, Nicholas A and Mulvaney-Day, Norah},
title = {Considerations for Opioid Use Disorder Treatment From Policy Makers’ Experiences With COVID-19 Policy Flexibilities},
journal = {Psychiatric Services},
year = {2024},
doi = {10.1176/appi.ps.20230260}
}
EUVIMED